Dr. Robin Schmidt

First author, “Prospective study on the immunological effects of conventional transarterial chemoembolization and high dose-rate brachytherapy in patients with hepatocellular carcinoma.”

Why did you choose to submit to ECIO?

ECIO is one of the world’s largest platforms for interventional oncology (IO) education and exchange, bringing together thousands of dedicated clinicians and researchers each year, both online and onsite. Being passionate about IO research myself, I was beyond excited at having the opportunity to not only share my own work, but also to experience cutting-edge lectures and discussions on the most advanced innovations in IO technology and clinical trials at ECIO’s annual conference.

Are there any special considerations to take into account when submitting a First@ECIO abstract?

First@ECIO represents a unique submission category for the most recent emerging clinical trials to be introduced to global IO experts for the very first time. Although early-stage clinical trials are suitable for submission, it may be reasonable to present publication-ready data with a fairly high-relevant impact on IO.

How did you find the submission process?

ECIO’s event website provides a well-structured overview of the submission process. Corresponding guidelines containing the most relevant information can be easily found as well. Once submitted, the notification service will confirm your current status and keep you further updated.

Do you have any tips for physicians considering submitting an abstract?

If you don’t take the chance, someone else might. IO education and innovation reach their peak at ECIO’s annual conference. Don’t miss the chance to join the global network of emerging and world-leading IO players.

Will you submit an abstract for ECIO 2023 as well?

Definitely, yes!